ID   WiDr
AC   CVCL_2760
SY   WiDR; WIDR; WiDr/S; WiDr-TC; WiDrTC; LED-WiDr; Led-WiDr
DR   BTO; BTO:0001483
DR   CLO; CLO_0009600
DR   EFO; EFO_0002389
DR   CLDB; cl4715
DR   CLDB; cl4988
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; CCL-218
DR   BCRC; 60157
DR   BioSample; SAMN03151797
DR   cancercelllines; CVCL_2760
DR   Cell_Model_Passport; SIDM00152
DR   ChEMBL-Cells; CHEMBL3307674
DR   ChEMBL-Targets; CHEMBL614647
DR   CLS; 300377
DR   ColonAtlas; WIDR
DR   Cosmic; 738928
DR   Cosmic; 887216
DR   Cosmic; 897740
DR   Cosmic; 905002
DR   Cosmic; 1066213
DR   Cosmic; 1122336
DR   Cosmic; 1132695
DR   Cosmic; 1184091
DR   Cosmic; 1187326
DR   Cosmic; 1218881
DR   Cosmic; 1466826
DR   Cosmic; 1479615
DR   Cosmic; 1609498
DR   Cosmic; 1676736
DR   Cosmic; 2651871
DR   Cosmic; 2664048
DR   Cosmic; 2668255
DR   Cosmic; 2760078
DR   ECACC; 85111501
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   FCS-free; 180-2-342-3-16-3
DR   GEO; GSM784020
DR   GEO; GSM827327
DR   GEO; GSM1006242
DR   GEO; GSM1006243
DR   GEO; GSM1006244
DR   GEO; GSM1374987
DR   GEO; GSM1374988
DR   GEO; GSM1448091
DR   GEO; GSM2550022
DR   IARC_TP53; 21
DR   ICLC; HTL00003
DR   IGRhCellID; WIDR
DR   JCRB; IFO50043
DR   JCRB; JCRB0224
DR   KCLB; 10218
DR   LINCS_HMS; 50049
DR   LINCS_LDP; LCL-1169
DR   MetaboLights; MTBLS227
DR   NCI-DTP; WIDR
DR   PharmacoDB; WIDR_1660_2019
DR   Progenetix; CVCL_2760
DR   PubChem_Cell_line; CVCL_2760
DR   RCB; RCB1908
DR   TKG; TKG 0513
DR   TKG; TKG 0516
DR   Wikidata; Q54994056
RX   CelloPub=CLPUB00271;
RX   PubMed=90012;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1389533;
RX   PubMed=1657424;
RX   PubMed=3335022;
RX   PubMed=3472642;
RX   PubMed=3518877;
RX   PubMed=4203458;
RX   PubMed=7874267;
RX   PubMed=8464898;
RX   PubMed=9290701;
RX   PubMed=9488600;
RX   PubMed=10674020;
RX   PubMed=10956384;
RX   PubMed=11414198;
RX   PubMed=16854228;
RX   PubMed=20143388;
RX   PubMed=20215515;
RX   PubMed=20570890;
RX   PubMed=23932154;
RX   PubMed=24042735;
RX   PubMed=25485619;
RX   PubMed=25926053;
RX   PubMed=25944804;
RX   PubMed=26537799;
RX   PubMed=26589293;
RX   PubMed=28683746;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00103.
CC   Population: Caucasian.
CC   Doubling time: 15 hours (PubMed=90012); 18 hours (PubMed=9488600); 45.68 hours (PubMed=25944804).
CC   HLA typing: A*01:01,24:03; B*35:01,44:03; C*04:01,04:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=24042735; PubMed=25926053; PubMed=28683746).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20570890; PubMed=24042735; PubMed=28683746).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (PubMed=24042735).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=24042735; PubMed=28683746).
CC   Omics: Deep exome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: RCB; RCB1908; true.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): ATCC; CLS; ECACC; JCRB; KCLB; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11 (CLS; JCRB)
ST   D13S317: 11,12 (ATCC; ECACC; KCLB; PubMed=25926053)
ST   D16S539: 11,12
ST   D18S51: 13
ST   D21S11: 29,30
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 10
ST   FGA: 20,22
ST   Penta D: 11,13
ST   Penta E: 14,16
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   CelloPub=CLPUB00271;
RA   Wallace R.E., Lindh D., Durr F.E.;
RT   "Studies on the development of resistance to mitoxantrone in human
RT   colon carcinoma cells in vitro.";
RL   Proc. Am. Assoc. Cancer Res. 23:767-767(1982).
//
RX   PubMed=90012; DOI=10.1007/BF02618407;
RA   Noguchi P.D., Wallace R.E., Johnson J., Earley E.M., O'Brien S.,
RA   Ferrone S., Pellegrino M.A., Milstien J., Needy C., Browne W.,
RA   Petricciani J.C.;
RT   "Characterization of the WiDr: a human colon carcinoma cell line.";
RL   In Vitro 15:401-408(1979).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V;
RA   Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R.,
RA   Lorenzoni M., Givel J.-C., Odartchenko N.;
RT   "Growth stimulation of a human colorectal carcinoma cell line by
RT   interleukin-1 and -6 and antagonistic effects of transforming growth
RT   factor beta 1.";
RL   Eur. J. Cancer 28:1894-1899(1992).
//
RX   PubMed=1657424; DOI=10.1007/BF00685821;
RA   Fischel J.-L., Formento P., Berlion M., Berille J., Gioanni J.,
RA   Bizzari J.-P., Milano G.;
RT   "Sequence-dependent cytotoxic effects of the combination of a new
RT   nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.";
RL   Cancer Chemother. Pharmacol. 28:448-454(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3472642; DOI=10.1016/0165-4608(87)90267-6;
RA   Chen T.-R., Drabkowski D., Hay R.J., Macy M.L., Peterson W.D. Jr.;
RT   "WiDr is a derivative of another colon adenocarcinoma cell line, HT-29.";
RL   Cancer Genet. Cytogenet. 27:125-134(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4203458;
RA   Petricciani J.C., Wallace R.E., McCoy D.W.;
RT   "A comparison of three in vivo assays for cell tumorigenicity.";
RL   Cancer Res. 34:105-108(1974).
//
RX   PubMed=7874267; DOI=10.1007/BF02349278;
RA   Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K.,
RA   Yachi A.;
RT   "Expression of cytoskeletal-associated protein tyrosine phosphatase
RT   PTPH1 mRNA in human hepatocellular carcinoma.";
RL   J. Gastroenterol. 29:727-732(1994).
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9488600; DOI=10.1007/s002800050744;
RA   Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G.,
RA   Schellens J.H.M.;
RT   "Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a
RT   panel of eight solid-tumor cell lines in vitro.";
RL   Cancer Chemother. Pharmacol. 41:307-316(1998).
//
RX   PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3;
RA   Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.;
RT   "Mutations in hMSH6 alone are not sufficient to cause the
RT   microsatellite instability in colorectal cancer cell lines.";
RL   Eur. J. Cancer 35:1724-1729(1999).
//
RX   PubMed=10956384; DOI=10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V;
RA   Backus H.H.J., Pinedo H.M., Wouters D., Padron J.M., Molders N.,
RA   van der Wilt C.L., van Groeningen C.J., Jansen G., Peters G.J.;
RT   "Folate depletion increases sensitivity of solid tumor cell lines to
RT   5-fluorouracil and antifolates.";
RL   Int. J. Cancer 87:771-778(2000).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=16854228; DOI=10.1186/1476-4598-5-29;
RA   Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N.,
RA   Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.;
RT   "Identification by real-time PCR of 13 mature microRNAs differentially
RT   expressed in colorectal cancer and non-tumoral tissues.";
RL   Mol. Cancer 5:29.1-29.10(2006).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032;
RA   Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A.,
RA   Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M.,
RA   Grade M., Gaedcke J.;
RT   "Identification of a microRNA expression signature for
RT   chemoradiosensitivity of colorectal cancer cells, involving
RT   miRNAs-320a, -224, -132 and let7g.";
RL   Radiother. Oncol. 108:451-457(2013).
//
RX   PubMed=24042735; DOI=10.1038/oncsis.2013.35;
RA   Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M.,
RA   Hektoen M., Lind G.E., Lothe R.A.;
RT   "Epigenetic and genetic features of 24 colon cancer cell lines.";
RL   Oncogenesis 2:e71.1-e71.8(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457;
RA   Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E.,
RA   Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R.,
RA   Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.;
RT   "Highly expressed genes in rapidly proliferating tumor cells as new
RT   targets for colorectal cancer treatment.";
RL   Clin. Cancer Res. 21:3695-3704(2015).
//
RX   PubMed=26537799; DOI=10.1074/mcp.M115.051235;
RA   Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J.,
RA   Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E.,
RA   Tollenaar R.A., Rombouts Y., Wuhrer M.;
RT   "N-glycosylation profiling of colorectal cancer cell lines reveals
RT   association of fucosylation with differentiation and caudal type
RT   homebox 1 (CDX1)/villin mRNA expression.";
RL   Mol. Cell. Proteomics 15:124-140(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28683746; DOI=10.1186/s12943-017-0691-y;
RA   Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J.,
RA   Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E.,
RA   Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.;
RT   "Multi-omics of 34 colorectal cancer cell lines -- a resource for
RT   biomedical studies.";
RL   Mol. Cancer 16:116.1-116.16(2017).
//